Skip to main content

Table 2 Antimicrobial activity of BMAP-27, BMAP-28, P19(9/B) and Tobramycin evaluated under different experimental conditions: “CF-like” (5% CO 2 , pH 6.8, SCFM) and “standard CLSI-recommended” (aerobiosis, pH 7.2, CAMHB)

From: Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia

Bacterial strains Susceptibility (MICCF-like/MICCLSI) to:
BMAP-27 BMAP-28 P19(9/B) TOBRAMYCIN
P. aeruginosa
Pa1 8/4 8/8 4/16 4/0.25
Pa5 8/4 16/16 8/8 16/2
Pa6 8/8 16/16 16/8 8/8
Pa9 8/4 16/16 16/8 64/1
Sm109 4/8 4/16 4/8 128/64
Sm126 8/16 8/32 4/32 256/64
Sm143 8/8 4/8 4/4 8/2
S. aureus     
Sa1 128/64 8/16 128/16 256/64
Sa3 64/64 4/32 64/16 256/16
Sa4 64/64 4/16 32/8 32/2
Sa7 64/16 4/16 64/8 256/2
Mean MIC CF-like /MIC CLSI 1.5 0.5 2.8 23.9
P. aeruginosa     
Pa1 8/8 8/16 16/32 4/1
Pa5 16/8 16/32 16/16 16/4
Pa6 16/8 16/16 16/32 8/8
Pa9 8/8 16/32 64/16 128/2
Sm109 8/16 8/16 8/8 256/128
Sm126 8/32 16/32 8/32 256/64
Sm143 16/8 8/8 4/4 8/8
Sa1 128/64 8/16 128/16 256/64
Sa3 64/64 4/32 64/16 256/32
Sa4 64/64 8/32 32/8 32/2
Sa7 64/NDa 8/16 64/8 256/4
Mean MBC CF-like /MBC CLSI 1.2 0.5 2.9 15.6
  1. a ND, not determined.